Vertex Pharmaceuticals Stock Is Down 13%. Here's Why You Should Buy the Dip
Vertex Pharmaceuticals (NASDAQ: VRTX) fell by 13% on Dec. 19, when the rare-disease drug developer reported some lackluster results from a late-stage clinical trial. But far from being a reason to doubt the long-term potential of this stock,
Jim Cramer on Vertex Pharmaceuticals Incporated (VRTX): ‘This Is Hardly Down For The Year. I Think It Can Still Go Lower’
We recently compiled a list of the Jim Cramer Discusses 17 Stocks And Blasts Zero Day Options. In this article, we are going to take a look at where Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) stands against the other stocks.
Vertex Pharmaceuticals Inc (VRTX) Stock: Analyzing Its Quiet Power
Vertex Pharmaceuticals Inc (VRTX) stock saw a modest uptick, ending the day at $408.18 which represents a slight increase of $2.91 or 0.72% from the prior close of $405.27. The stock opened at $401.53 and touched a low of $401.
Vertex Pharmaceuticals Stock Heads for Worst Day in 4 Years
Vertex Pharmaceuticals (VRTX) is plummeting after disappointing trial results, headed for its worst day in four years
Vertex Pharmaceuticals (NASDAQ:VRTX) Given New $430.00 Price Target at Scotiabank
Vertex Pharmaceuticals (NASDAQ:VRTX – Free Report) had its target price hoisted by Scotiabank from $426.00 to $430.00 in a research report released on Monday morning,Benzinga reports. They currently have a sector perform rating on the pharmaceutical company’s stock.
Vertex Pharmaceuticals Inc (VRTX) Stock Rated Buy by H.C. Wainwright
Vertex Pharmaceuticals Inc (VRTX) stock saw a modest uptick, ending the day at $405.27 which represents a slight increase of $8.00 or 2.01% from the prior close of $397.27. The stock opened at $391.87 and touched a low of $390.
Vertex Pharmaceuticals Inc. stock rises Tuesday, still underperforms market
Shares of Vertex Pharmaceuticals Inc. VRTX inched 0.72% higher to $408.18 Tuesday, on what proved to be an all-around favorable trading session for the stock market, with the S&P 500 Index SPX rising 1.
Vertex Pharmaceuticals (VRTX) Gains But Lags Market: What You Should Know
Vertex Pharmaceuticals (VRTX) closed the most recent trading day at $408.18, moving +0.72% from the previous trading session. The stock trailed the S&P 500, which registered a daily gain of 1.1%. Elsewhere,
Zacks Research Has Positive Estimate for VRTX Q3 Earnings
Equities researchers at Zacks Research upped their Q3 2025 earnings per share estimates for shares of Vertex Pharmaceuticals ...
Shareholder Rights Advocates at Levi & Korsinsky Investigate Vertex Pharmaceuticals Incorporated (VRTX) Regarding Possible Securities Fraud Violations
NEW YORK, NY / ACCESSWIRE / December 26, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Vertex ...
Vertex Pharmaceuticals: Alyftrek Is An 'Accretive Opportunity' On Top- And Bottom-Lines, Says Bullish Analyst
Vertex Pharmaceuticals announced FDA approval for Alyftrek, which expands the company's CF franchise to address around 6,000 ...
Zacks.com on MSN4d
Vertex Secures FDA Approval for New Cystic Fibrosis Drug Alyftrek
The FDA's nod is based on late-stage data, which show that treatment with VRTX's Alyftrek enhances patient benefit compared ...
Analysts Are Bullish on Top Healthcare Stocks: Oruka Therapeutics (ORKA), Vertex Pharmaceuticals (VRTX)
There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Oruka Therapeutics (ORKA – Research Report), ...
Vertex Pharmaceuticals price target lowered to $460 from $550 at Truist
Truist analyst Joon Lee lowered the firm’s price target on Vertex Pharmaceuticals (VRTX) to $460 from $550 and keeps a Buy ...